A carregar...
Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
BACKGROUND: We assessed the safety profile of lasmiditan, a selective 5-HT(1F) receptor agonist without vasoconstrictive activity being developed as an acute therapy for migraine. METHODS: SAMURAI and SPARTAN were Phase 3 double-blind studies of patients with migraine, randomized to oral lasmiditan...
Na minha lista:
| Publicado no: | Cephalalgia |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6787764/ https://ncbi.nlm.nih.gov/pubmed/31166697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102419855080 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|